Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026), Mineola
Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
Memorial Sloan Kettering Cancer Center ( Site 5002), New York

Menerima pesertaFase 1/2

Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07049926

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #60, New York
Exelixis Clinical Site #6, New York
Exelixis Clinical Site #76, Syracuse

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Roswell Park Comprehensive, Buffalo

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05287945

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
dan 3 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT03866382

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NYU Langone Medical Center, New York

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04981119

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Memorial Sloan Kettering Cancer Center ( Site 0126), New York

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07489495

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07293351

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Columbia University Irving Medical Center, New York

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06863311

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Northwell Health Imbert Cancer Center, Bay Shore
Memorial Sloan Kettering Commack, Commack
Glens Falls Hospital, Glens Falls
dan 10 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

New York Oncology Hematology, P.C., Albany
New York Oncology Hematology - Clifton Park Cancer Center, Clifton Park
MSK Commack, Commack
dan 7 lainnya

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07227415

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07195916

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
Columbia University, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT04977453

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Roswell Park Cancer Institute, Buffalo
Hematology Oncology Associates of CNY at Camillus, Camillus
Memorial Sloan Kettering Commack, Commack
dan 13 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06661720

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
dan 1 lainnya

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05837767

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

New York Cancer & Blood Specialists, New York
University of Rochester - Wilmot Cancer Institute, Rochester

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06582017

Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

Roswell Park Comprehensive Cancer Center, Buffalo

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07714018

A Study of MGC026 in Participants With Advanced Solid Tumors

START-New York Long Island, Lake Success

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06242470

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Memorial Sloan Kettering Cancer Center, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT07195682

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Xencor Investigative Site, New York
Xencor Investigative Site, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05433142

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

NYU Langone Health Perlmutter Cancer Center, New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University - The Trustees of Columbia University in the City of New York, New York
dan 2 lainnya

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT03972657

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
dan 1 lainnya

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT06835972

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT04777994

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Northwell Health, Lake Success

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Apr 2026 · NCT06413680

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

UB/ Great Lakes Cancer Care, Buffalo

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT06222593

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
dan 1 lainnya

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT06699602

Decision Aid (DA) for Renal Patients

NYU Langone Health, New York

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Des 2025 · NCT05387863

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NYU Langone Health, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT06682793

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Roswell Park Cancer Institute, Buffalo
Northwell Health/Center for Advanced Medicine, Lake Success
University of Rochester, Rochester
dan 1 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT04510597

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Memorial Sloan-Kettering Cancer Center, New York

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Nov 2024 · NCT05824975

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Roswell Park Cancer Institute, Buffalo

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Nov 2024 · NCT04787042

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.